Showing results (11-20 of 14) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
The Lancet. Oncology|October 13, 2018
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trialJudith Trotman, Sally F Barrington, David Belada, et al.Blood|July 29, 2006
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialMarinus H J van Oers, Richard Klasa, Robert E Marcus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup studyMarinus H J van Oers, Evelyn Tönnissen, Martine Van Glabbeke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2018
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and SafetyWolfgang Hiddemann, Anna Maria Barbui, Miguel A Canales, et al.Pageof 2